Life Care News
A Hope Of True Information

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium


— WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors —

— WU-NK-101 exhibited robust trafficking, intra-tumor infiltration, and persistence in xenograft tumor models which were further enhanced when combined with monoclonal antibodies (mAbs)

— WU-NK-101 maintained robust cytotoxicity in the tumor microenvironment (TME), including against primary CRC samples in the “native” TME —

— WU-NK-101 demonstrated superior anti-tumor efficacy against colorectal cancer (CRC) tumor cell lines in vivo and in vitro compared to cetuximab (Ctx) monotherapy; efficacy was further augmented when deployed in combination —

Data support clinical development of WU-NK-101 for CRC and other solid tumor indications —

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented preclinical data on WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, in combination with cetuximab (Ctx), at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place January 19-21, 2023, in San Francisco, California.

“Our best-in-class memory NK cell platform is uniquely designed to have broad applications across solid and liquid tumors,” said Jan Davidson-Moncada, M.D., Ph.D., Chief Medical Officer of Wugen.“WU-NK-101 has a unique CIML phenotype with enhanced metabolic fitness/flexibility and decreased susceptibility to immunosuppression—key properties that in combination with these data, build our conviction in the development trajectory for WU-NK-101 as a novel treatment for solid tumor cancers. We plan to initiate a first-in-human study of WU-NK-101 in combination with cetuximab for CRC in addition to SCCHN later this year.”

Today’s presentation highlighted the following:

  • WU-NK-101 potency against colorectal cancer (CRC) cells was further enhanced when combined with Ctx in vitro and in vivo, confirming an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action. WU-NK-101 in combination with Ctx showed improved CRC cell killing compared to WU-NK-101 and Ctx monotherapy.
  • WU-NK-101 showed robust homing to the TME, which was further improved when combined with monoclonal antibodies (mAbs). Intra-tumor penetration and persistence was also increased when combined with mAb in in vivo models.
  • WU-NK-101 displayed enhanced metabolic fitness/flexibility and maintained cytotoxicity within adverse, immunosuppressive tumor microenvironment (TME)-aligned media as compared to conventional NK (cNK) and T-cells. WU-NK-101 cells maintained cytotoxicity in a 3D TME model with native cellular components from primary CRC samples.
  • A Phase 1b clinical trial of WU-NK-101 in combination with Ctx for advanced and/or metastatic CRC and advanced and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) is in development.

The details of Wugen’s presentation at ASCO Gastrointestinal Cancers Symposium are as follows:

Title: WU-NK-101, an Enhanced Memory Natural Killer (NK) Cell Therapy, with Cetuximab (Ctx) for the Treatment of Advanced Colorectal Cancer (CRC).

Abstract Number: 170

Session Name: Poster Session C: Cancers of the Colon, Rectum, and Anus

Session Date and Time: Saturday, January 21, 2023 from 9:30 a.m. – 10:55 a.m. ET

Location: On Demand | Level 1, West Hall

Presenting Author: John Muth, Wugen

Additional meeting information can be found at

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit


Elsie Yau, Stern Investor Relations, Inc.


Get real time updates directly on you device, subscribe now.